Investigational new drug, company code: BGG492 + Placebo + Investigational new drug, company code: BGG492
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Partial Onset Seizures
Conditions
Partial Onset Seizures
Trial Timeline
Jun 1, 2010 → Sep 1, 2011
NCT ID
NCT01147003About Investigational new drug, company code: BGG492 + Placebo + Investigational new drug, company code: BGG492
Investigational new drug, company code: BGG492 + Placebo + Investigational new drug, company code: BGG492 is a phase 2 stage product being developed by Novartis for Partial Onset Seizures. The current trial status is completed. This product is registered under clinical trial identifier NCT01147003. Target conditions include Partial Onset Seizures.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01147003 | Phase 2 | Completed |
Competing Products
20 competing products in Partial Onset Seizures
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E2007 | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Pre-clinical | 23 |
| perampanel + perampanel | Eisai | Phase 1 | 33 |
| perampanel + perampanel + perampanel + Placebo | Eisai | Phase 3 | 77 |
| Perampanel + Placebo | Eisai | Approved | 85 |
| Perampanel and Microgynon-30 + Perampanel and Microgynon-30 | Eisai | Phase 1 | 33 |
| perampanel | Eisai | Phase 2 | 52 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Zonisamide + Placebo | Eisai | Phase 3 | 77 |
| zonisamide | Eisai | Pre-clinical | 23 |
| E2007 (perampanel) + E2007 (perampanel) + Placebo | Eisai | Phase 3 | 77 |
| Perampanel + Placebo | Eisai | Phase 3 | 77 |
| E2007 (perampanel) + E2007 (perampanel) + Placebo | Eisai | Phase 3 | 77 |
| Adjunctive Zonisamide + Replacement with Zonisamide | Eisai | Approved | 85 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Zonisamide + Placebo | Eisai | Phase 3 | 77 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Rufinamide | Eisai | Phase 3 | 77 |
| Zonisamide | Eisai | Phase 3 | 77 |
| Eslicarbazepine Acetate tablets | Eisai | Pre-clinical | 23 |